Most Recent
Melbourne property developer Steller has been put into receivership, a dramatic collapse for a firm that once boasted a pipeline of $4.2 billion worth of projects.
Clothing manufacturer IFOTA has been ordered to open its books to shareholder Simba after it raised concerns about IFOTA's management and financial position.
Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.
Medical device manufacturer American Medical Systems has reasserted that it cannot face claims under Australian consumer laws over its allegedly defective vaginal mesh products because it only supplied the products to a US subsidiary.
A court has found Ariosa Diagnostics infringed a patent held by Sequenom for a noninvasive prenatal genetic test, and ruled one claim of the patent invalid for lack of fair basis.
Bega Cheese is accusing global food giant Mondelez of overstating the value of the Australian assets purchased for $460 million in July 2017 as part of a deal that's also at the centre of an ongoing dispute with Kraft over peanut butter trade dress rights.
IOOF subsidiary Australian Executor Trustees (SA) is facing an $82 million claim for compensation by investors angered by the way the trustee handled the sale of a 42,000 hectare timber plantation run by collapsed forestry giant Gunns Group.
A unit of Suncorp Group has been hit with a class action over superannuation fees and charges, the eighth banking royal commission-related class action filed thus far.
A judge has released his reasons for consolidating two shareholder class actions against logistics company Brambles over opposition by the lead applicant in one of the competing cases, saying the interests of group members trumped those of the lawyers and funders in the case.
The Australian Securities and Investments Commission is challenging the dismissal of its enforcement action against National Australia Bank contractor Whitebox Trading and sole director Johannes Boshoff, which accused them of market manipulation that resulted in a spike in the price of securities on the ASX-200 index in October 2012.